{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:02:31Z","timestamp":1782370951342,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40120-025-00773-3","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T06:09:29Z","timestamp":1750054169000},"page":"1641-1656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA"],"prefix":"10.1007","volume":"14","author":[{"given":"Sophia","family":"Woodson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Gettings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Yueh","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-0460","authenticated-orcid":false,"given":"Sylvia","family":"Klineova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-5597","authenticated-orcid":false,"given":"Rebecca S.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aljoeson","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinyee","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-5542","authenticated-orcid":false,"given":"Jason P.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Belviso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-9113","authenticated-orcid":false,"given":"James B.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-8360","authenticated-orcid":false,"given":"Sai L.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"773_CR1","unstructured":"MS International Federation. Atlas of MS. 2023. https:\/\/www.atlasofms.org\/map\/united-states-of-america\/epidemiology\/number-of-people-with-ms#about. Accessed 19 Oct 2023."},{"key":"773_CR2","unstructured":"Bureau USC. QuickFacts. 2023. https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/RHI225222. Accessed 2023."},{"issue":"19","key":"773_CR3","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1212\/WNL.0b013e3182918cc2","volume":"80","author":"A Langer-Gould","year":"2013","unstructured":"Langer-Gould A, Brara SM, Beaber BE, Zhang JL. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013;80(19):1734\u20139.","journal-title":"Neurology"},{"issue":"11","key":"773_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11910-019-1000-5","volume":"19","author":"VP Cipriani","year":"2019","unstructured":"Cipriani VP, Klein S. Clinical characteristics of multiple sclerosis in African-Americans. Curr Neurol Neurosci Rep. 2019;19(11):87.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"773_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1212\/WNL.0b013e3181e8e72a","volume":"75","author":"I Kister","year":"2010","unstructured":"Kister I, Chamot E, Bacon JH, et al. Rapid disease course in African Americans with multiple sclerosis. Neurology. 2010;75(3):217\u201323.","journal-title":"Neurology"},{"issue":"2","key":"773_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1212\/CPJ.0000000000000112","volume":"5","author":"O Khan","year":"2015","unstructured":"Khan O, Williams MJ, Amezcua L, et al. Multiple sclerosis in US minority populations: clinical practice insights. Neurol Clin Pract. 2015;5(2):132\u201342.","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"773_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40120-020-00193-5","volume":"9","author":"MJ Williams","year":"2020","unstructured":"Williams MJ, Amezcua L, Okai A, et al. Real-world safety and effectiveness of dimethyl fumarate in Black or African American patients with multiple sclerosis: 3-year results from ESTEEM. Neurol Ther. 2020;9(2):483\u201393.","journal-title":"Neurol Ther"},{"key":"773_CR8","volume":"11","author":"BE Turner","year":"2022","unstructured":"Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race\/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am. 2022;11:100252.","journal-title":"Lancet Reg Health Am"},{"issue":"2","key":"773_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","volume":"34","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase\u00a0III EVOLVE-MS-2 study. CNS Drugs. 2020;34(2):185\u201396.","journal-title":"CNS Drugs"},{"key":"773_CR10","unstructured":"Vumerity [prescribing information]. Biogen Inc., Cambridge MA, 2024. https:\/\/www.vumerityhcp.com\/content\/dam\/commercial\/vumerity\/hcp\/en_us\/pdf\/vumerity-prescribing-information.pdf. Accessed 18 Dec 2024."},{"key":"773_CR11","unstructured":"Tecfidera [prescribing information]. Biogen Inc., Cambridge, MA, 2024. https:\/\/www.tecfidera.com\/content\/dam\/commercial\/multiple-sclerosis\/tecfidera\/pat\/en_us\/pdf\/full-prescribing-info.pdf. Accessed 18 Dec 2024."},{"issue":"2","key":"773_CR12","first-page":"205521732412471","volume":"10","author":"T Spelman","year":"2024","unstructured":"Spelman T, Eichau S, Alroughani R, et al. Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: real-world evidence from MSBase. Mult Scler J Exp Transl Clin. 2024;10(2):20552173241247184.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"8","key":"773_CR13","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1007\/s12325-024-02901-1","volume":"41","author":"JD Bowen","year":"2024","unstructured":"Bowen JD, Stulc J, Hunter SF, et al. Diroximel fumarate in patients with relapsing\u2013remitting multiple sclerosis: NEDA-3 after re-baselining in the phase\u00a03 EVOLVE-MS-1 study. Adv Ther. 2024;41(8):3396\u2013406.","journal-title":"Adv Ther"},{"issue":"2","key":"773_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40120-017-0077-5","volume":"6","author":"RJ Fox","year":"2017","unstructured":"Fox RJ, Gold R, Phillips JT, et al. Efficacy and tolerability of delayed-release dimethyl fumarate in Black, Hispanic, and Asian patients with relapsing-remitting multiple sclerosis: post hoc integrated analysis of DEFINE and CONFIRM. Neurol Ther. 2017;6(2):175\u201387.","journal-title":"Neurol Ther"},{"issue":"6","key":"773_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1177\/1756285616661929","volume":"9","author":"L Zhovtis Ryerson","year":"2016","unstructured":"Zhovtis Ryerson L, Green R, Confident G, et al. Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis. Ther Adv Neurol Disord. 2016;9(6):454\u201361.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"773_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12883-018-1220-3","volume":"19","author":"T Saida","year":"2019","unstructured":"Saida T, Yamamura T, Kondo T, et al. A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries. BMC Neurol. 2019;19(1):5.","journal-title":"BMC Neurol"},{"issue":"5","key":"773_CR17","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s40120-023-00517-1","volume":"12","author":"MJ Williams","year":"2023","unstructured":"Williams MJ, Amezcua L, Chinea A, et al. Real-world safety and effectiveness after 5\u00a0years of dimethyl fumarate treatment in Black and Hispanic patients with multiple sclerosis in ESTEEM. Neurol Ther. 2023;12(5):1669\u201382.","journal-title":"Neurol Ther"},{"key":"773_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105912","volume":"91","author":"SF Hunter","year":"2024","unstructured":"Hunter SF, Lindsey JW, Osborne B, et al. Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase\u00a03 EVOLVE-MS-1 study. Mult Scler Relat Disord. 2024;91: 105912.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"773_CR19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41582-022-00735-5","volume":"18","author":"R Dobson","year":"2022","unstructured":"Dobson R, Rice DR, D\u2019Hooghe M, et al. Social determinants of health in multiple sclerosis. Nat Rev Neurol. 2022;18(12):723\u201334.","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"773_CR20","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1001\/jamaneurol.2021.3416","volume":"78","author":"L Amezcua","year":"2021","unstructured":"Amezcua L, Rivera VM, Vazquez TC, Baezconde-Garbanati L, Langer-Gould A. Health disparities, inequities, and social determinants of health in multiple sclerosis and related disorders in the US: a review. JAMA Neurol. 2021;78(12):1515\u201324.","journal-title":"JAMA Neurol"},{"key":"773_CR21","unstructured":"Komodo Race & Ethnicity Data: User Guide Version V23.8. Komodo Health Inc.; 2024."},{"issue":"6","key":"773_CR22","first-page":"469","volume":"8","author":"DA Ollendorf","year":"2002","unstructured":"Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8(6):469\u201376.","journal-title":"J Manag Care Pharm"},{"issue":"12","key":"773_CR23","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jclinepi.2008.01.006","volume":"61","author":"ME Charlson","year":"2008","unstructured":"Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234\u201340.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"773_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"11","key":"773_CR25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"12","key":"773_CR26","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","volume":"57","author":"V Sundararajan","year":"2004","unstructured":"Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288\u201394.","journal-title":"J Clin Epidemiol"},{"key":"773_CR27","doi-asserted-by":"crossref","unstructured":"Nicholas J, Ontaneda D, Carraro M, et al. Development of an algorithm to identify multiple sclerosis (MS) disease severity based on healthcare costs in a US Administrative Claims Database (P2.052). Neurology. 2017;88(16 Supplement):P2.052.","DOI":"10.1212\/WNL.88.16_supplement.P2.052"},{"key":"773_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102539","volume":"46","author":"J Toliver","year":"2020","unstructured":"Toliver J, Barner JC, Lawson K, Sonawane K, Rascati K. Replication of a claims-based algorithm to estimate multiple sclerosis disease severity in a commercially insured population. Mult Scler Relat Disord. 2020;46:102539.","journal-title":"Mult Scler Relat Disord"},{"key":"773_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102741","volume":"49","author":"JC Toliver","year":"2021","unstructured":"Toliver JC, Barner JC, Lawson KA, Rascati KL. Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population. Mult Scler Relat Disord. 2021;49:102741.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"773_CR30","first-page":"184","volume":"62","author":"PA Meyer","year":"2013","unstructured":"Meyer PA, Penman-Aguilar A, Campbell VA, et al. Conclusion and future directions: CDC health disparities and inequalities report\u2014United States, 2013. MMWR Suppl. 2013;62(3):184\u20136.","journal-title":"MMWR Suppl"},{"issue":"12","key":"773_CR31","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1185\/03007995.2013.847411","volume":"29","author":"N Bergvall","year":"2013","unstructured":"Bergvall N, Makin C, Lahoz R, et al. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin. 2013;29(12):1647\u201356.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"773_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40801-021-00251-w","volume":"8","author":"L Freeman","year":"2021","unstructured":"Freeman L, Kee A, Tian M, Mehta R. Retrospective claims analysis of treatment patterns, relapse, utilization, and cost among patients with multiple sclerosis initiating second-line disease-modifying therapy. Drugs Real World Outcomes. 2021;8(4):497\u2013508.","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"773_CR33","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0127","volume":"12","author":"L Araujo","year":"2023","unstructured":"Araujo L, Kyatham S, Bzdek KG, Higuchi K, Greene N. Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA. J Comp Eff Res. 2023;12(1):e220127.","journal-title":"J Comp Eff Res"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00773-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:06:40Z","timestamp":1757196400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00773-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00773-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sophia Woodson served on scientific advisory or data safety monitoring boards for MSSA and Sanofi, and served on speaker bureaus for Biogen, Bristol Myers Squibb, and Genentech. Edward J. Gettings, Jong-Mi Lee, and Aljoeson Walker declare that they have no competing interests. Chu-Yueh Guo has received consulting fees from Genentech and Horizon. Sylvia Klineova declares having non-promotional speaking with Biogen and Alexion, advisory work with Amgen and TG Therapeutics, and research support from Biogen. Rebecca S. Romero has received consulting fees from Alexion, EMD Serono, Genentech, Horizon, and TG Therapeutics. Kinyee Fong, Jason P. Mendoza, Nicholas Belviso, Boyang Bian, James B. Lewin, and Sai L. Shankar are all employees of Biogen and may hold stock in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was a retrospective analysis of de-identified data from the Komodo Health database and did not involve any new studies with human or animal subjects. As such, ethical approval or informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}